BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...the deal in 2017 and discontinued development of HCV regimen JNJ-4178, which combined the biotech’s odalasvir...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...the deal in 2017 and discontinued development of HCV regimen JNJ-4178, which combined the biotech’s odalasvir...
BioCentury | Oct 27, 2017
Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

...Therapeutics Inc. , San Diego, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Chemistry Allison Johnson ACH-3102 AL-335 JNJ-4178 LUNAR-HBV simeprevir Achillion...
BioCentury | Sep 15, 2017
Company News

J&J drops Achillion HCV deal

...JNJ-4178 is an oral combination of Achillion's odalasvir (ACH-3102) plus J&J's AL-335 and Olysio simeprevir. Odalasvir...
BioCentury | Sep 12, 2017
Company News

Achillion down after J&J drops HCV compound

...an oral combination of Achillion's odalasvir ( ACH-3102 ) plus J&J's AL-335 and Olysio simeprevir. Odalasvir...
BioCentury | Dec 30, 2016
Clinical News

JNJ-4178: Ph IIb OMEGA-1 started

...in about 300 patients without cirrhosis. JNJ-4178 comprises 800 mg AL-335 from J&J, 25 mg odalasvir...
...HCV NS5A protein Description: Oral combination of AL-335 , an HCV NS5B polymerase inhibitor; odalasvir (ACH-3102...
...quality of life (QOL), fatigue severity, pharmacokinetics and safety Status: Phase IIb started Milestone: NA Julian Zhu ACH-3102 AL-335 odalasvir Olysio simeprevir Achillion...
BioCentury | Oct 3, 2016
Clinical News

AL-335: Interim Phase IIa data

...odalasvir and Olysio simeprevir. In cohort 1 (n=20), once-daily 400 mg AL-335 plus 50 mg odalasvir...
...in 100% of patients. In cohort 2 (n=20), once-daily 800 mg AL-335 plus 50 mg odalasvir...
...and regimens containing >=1 HCV asset from Achillion, including odalasvir (see BioCentury, May 25, 2015). Odalasvir...
BioCentury | Oct 3, 2016
Clinical News

Odalasvir: Interim Phase IIa data

...odalasvir and Olysio simeprevir. In cohort 1 (n=20), once-daily 400 mg AL-335 plus 50 mg odalasvir...
...in 100% of patients. In cohort 2 (n=20), once-daily 800 mg AL-335 plus 50 mg odalasvir...
...Inc. (NASDAQ:ACHN), New Haven, Conn. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Odalasvir ( ACH-3102...
BioCentury | Oct 3, 2016
Finance

ASH and others

...a 100% SVR12 rate in a Phase II study. The regimen included Achillion's odalasvir ( ACH-3102...
BioCentury | Sep 23, 2016
Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

...study, received a combination including J&J's Olysio simeprevir and AL-335 , plus Achillion's odalasvir ( ACH-3102...
...via its acquisition of Alios Biopharma Inc. in 2014, and received exclusive, worldwide rights to odalasvir...
...in 100% of patients in two other eight-week cohorts. A regimen with only AL-335 and odalasvir...
Items per page:
1 - 10 of 79